Commentary

Striking the balance: Who should be screened for CP-CRE acquisition?


 

1. Weiner LM, Fridkin SK, Aponte-Torres Z, Avery L, Coffin N, Dudeck MA, Edwards JR, Jernigan JA, Konnor R, Soe MM, Peterson K, Clifford McDonald L. Vital signs: preventing antibiotic-resistant infections in hospitals - United States, 2014. Am J Transplant. 2016 Jul;16(7):2224-30.

2. Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update – CRE Toolkit.

3. Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2014 Mar;58(5):697-703.

Schwartz-Neiderman A, Braun T, Fallach N, Schwartz D, Carmeli Y, Schechner V. Risk factors for carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) acquisition among contacts of newly diagnosed CP-CRE patients. Infect Control Hosp Epidemiol. 2016 Jul 25:1-7.

Vered Schechner, MD, MSc, is an infection control physician in the department of epidemiology at Tel Aviv Sourasky Medical Center.

Pages

Recommended Reading

Hospitals increase CRE risk when they share patients
MDedge Internal Medicine
FDA rule will pull many consumer antibacterial soaps from market
MDedge Internal Medicine
Antibiotic susceptibility differs in transplant recipients
MDedge Internal Medicine
Fourth U.S. case of mcr-1–resistance gene reported
MDedge Internal Medicine
WHO updates ranking of critically important antimicrobials
MDedge Internal Medicine
Many patients with diabetic foot infections get unnecessary MRSA treatment
MDedge Internal Medicine
New drugs poised to stem tide of antibacterial resistance in gonorrhea
MDedge Internal Medicine
Gonorrhea cluster shows increased antibiotic resistance
MDedge Internal Medicine
Hospital managers identify barriers to antimicrobial stewardship
MDedge Internal Medicine
Ceftazidime-avibactam stands up to CRE, but resistance a problem
MDedge Internal Medicine